ES2902879T3 - Método de cuantificación de células inmunitarias en tejidos tumorales y sus aplicaciones - Google Patents

Método de cuantificación de células inmunitarias en tejidos tumorales y sus aplicaciones Download PDF

Info

Publication number
ES2902879T3
ES2902879T3 ES13731071T ES13731071T ES2902879T3 ES 2902879 T3 ES2902879 T3 ES 2902879T3 ES 13731071 T ES13731071 T ES 13731071T ES 13731071 T ES13731071 T ES 13731071T ES 2902879 T3 ES2902879 T3 ES 2902879T3
Authority
ES
Spain
Prior art keywords
tumor
cells
stained
density
tissue
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES13731071T
Other languages
English (en)
Spanish (es)
Inventor
Jérôme Galon
Franck Pagès
Bernhard Mlecnik
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Universite Paris Cite
Original Assignee
Assistance Publique Hopitaux de Paris APHP
Institut National de la Sante et de la Recherche Medicale INSERM
Universite de Paris
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Assistance Publique Hopitaux de Paris APHP, Institut National de la Sante et de la Recherche Medicale INSERM, Universite de Paris filed Critical Assistance Publique Hopitaux de Paris APHP
Application granted granted Critical
Publication of ES2902879T3 publication Critical patent/ES2902879T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/5759—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds localised on the membrane of tumour or cancer cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Oncology (AREA)
  • Hospice & Palliative Care (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
ES13731071T 2012-06-14 2013-06-14 Método de cuantificación de células inmunitarias en tejidos tumorales y sus aplicaciones Active ES2902879T3 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IB2012001446 2012-06-14
PCT/EP2013/062405 WO2013186374A1 (en) 2012-06-14 2013-06-14 Method for quantifying immune cells in tumoral tissues and its applications

Publications (1)

Publication Number Publication Date
ES2902879T3 true ES2902879T3 (es) 2022-03-30

Family

ID=46881097

Family Applications (1)

Application Number Title Priority Date Filing Date
ES13731071T Active ES2902879T3 (es) 2012-06-14 2013-06-14 Método de cuantificación de células inmunitarias en tejidos tumorales y sus aplicaciones

Country Status (13)

Country Link
US (1) US10317408B2 (enExample)
EP (1) EP2861986B1 (enExample)
JP (1) JP6449765B2 (enExample)
KR (1) KR102179848B1 (enExample)
CN (1) CN104541167B (enExample)
AU (1) AU2013276470B2 (enExample)
BR (1) BR112014031143B8 (enExample)
CA (1) CA2873278C (enExample)
DE (1) DE13731071T1 (enExample)
ES (1) ES2902879T3 (enExample)
IL (1) IL235738B (enExample)
SG (1) SG11201408107RA (enExample)
WO (1) WO2013186374A1 (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK3111221T4 (da) 2014-02-24 2022-04-19 Ventana Med Syst Inc Fremgangsmåder, kit og systemer til scoring af immunresponsen mod cancer ved samtidig påvisning af CD3, CD8, CD20 og FOXP3
CA2955156C (en) * 2014-09-03 2024-04-30 Ventana Medical Systems, Inc. Systems and methods for generating fields of view
WO2016073760A1 (en) * 2014-11-05 2016-05-12 The Regents Of The University Of California Methods for stratifying non-responders to therapies that block pd1/pdl1 axis
US10632151B2 (en) 2015-01-22 2020-04-28 University Of Massachusetts Cancer immunotherapy
WO2017070585A1 (en) * 2015-10-23 2017-04-27 Novartis Ag Method of scoring a sample comprising tumor tissue
CN109690314B (zh) * 2016-05-09 2022-08-02 法国国家卫生及研究医学协会 患有实体癌症的患者的分类方法
US11315240B2 (en) * 2016-05-18 2022-04-26 Hoffmann-La Roche Inc. System and method of tumor classification
US12158399B2 (en) * 2016-08-05 2024-12-03 Duke University CaMKK2 inhibitor compositions and methods of using the same
JP7356904B2 (ja) * 2016-10-27 2023-10-05 コーニンクレッカ フィリップス エヌ ヴェ １つ又は複数の組織サンプルにおける細胞組成情報を決定する装置
CA3037046A1 (en) 2016-10-31 2018-05-03 University Of Massachusetts Targeting microrna-101-3p in cancer therapy
CN106846310A (zh) * 2017-01-19 2017-06-13 宁波江丰生物信息技术有限公司 一种基于免疫组化技术的病理辅助分析方法
EP3659110A1 (en) * 2017-07-24 2020-06-03 Ventana Medical Systems, Inc. Methods and systems for evaluation of immune cell infiltrate in tumor samples
US11814623B2 (en) 2018-01-30 2023-11-14 University Of Massachusetts Methods of treating a wound using epigenetic regulation
ES2965647T3 (es) 2018-01-31 2024-04-16 Ventana Med Syst Inc Procedimientos y sistemas para la evaluación de infiltrado de células inmunitarias en cáncer colorrectal en estadio III
JP7411667B2 (ja) * 2019-02-05 2024-01-11 ヴェンタナ メディカル システムズ， インク． ステージｉｖの結腸直腸がんにおける免疫細胞浸潤の評価のための方法及びシステム
SG11202112712RA (en) 2019-06-03 2021-12-30 Inst Nat Sante Rech Med Methods for modulating a treatment regimen
MX2022004501A (es) 2019-11-07 2022-05-06 Oncxerna Therapeutics Inc Clasificacion de microambientes tumorales.
CN111551546B (zh) * 2020-06-01 2023-01-03 南京瑟斯检测科技有限公司 一种基于光学微腔结构超材料的免疫组化便捷检测方法
WO2022002874A1 (en) 2020-06-30 2022-01-06 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapy and radical surgery
EP4172621A1 (en) 2020-06-30 2023-05-03 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods for predicting the risk of recurrence and/or death of patients suffering from a solid cancer after preoperative adjuvant therapies
TWI838687B (zh) * 2021-01-30 2024-04-11 奇美醫療財團法人奇美醫院 評估腫瘤標本免疫狀態的方法
CN113092202A (zh) * 2021-03-25 2021-07-09 上海福君基因生物科技有限公司 一种胃癌预后预测装置
CN113515077A (zh) * 2021-04-23 2021-10-19 重庆德方信息技术有限公司 人体细胞染色过程监控系统及方法
JP2024530213A (ja) 2021-08-10 2024-08-16 ルニット・インコーポレイテッド 病理スライド画像に関する情報を出力する方法及び装置
WO2023175366A1 (en) 2022-03-17 2023-09-21 Veracyte Methods for predicting response to an immunotherapeutic treatment in a patient with a cancer
CN121263449A (zh) 2023-03-21 2026-01-02 拜格拉夫55公司 Cd19/cd38多特异性抗体
CN116646088B (zh) * 2023-07-27 2023-12-01 广东省人民医院 一种预测方法、装置、设备及介质

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69627183T2 (de) * 1995-11-30 2004-01-29 Chromavision Med Sys Inc Verfahren zur automatischen bildanalyse biologischer proben
EP1777523A1 (en) * 2005-10-19 2007-04-25 INSERM (Institut National de la Santé et de la Recherche Médicale) An in vitro method for the prognosis of progression of a cancer and of the outcome in a patient and means for performing said method
CA2628317C (en) * 2005-12-19 2015-12-08 Ventana Medical Systems, Inc. Automated lean methods in anatomical pathology
WO2010033508A1 (en) 2008-09-16 2010-03-25 Historx, Inc. Reproducible quantification of biomarker expression
FR2964744B1 (fr) * 2010-09-10 2015-04-03 Univ Versailles St Quentin En Yvelines Test pronostic de l'evolution d'une tumeur solide par analyse d'images

Also Published As

Publication number Publication date
BR112014031143A2 (pt) 2017-08-08
EP2861986A1 (en) 2015-04-22
BR112014031143B8 (pt) 2022-11-22
AU2013276470A1 (en) 2014-11-27
CN104541167A (zh) 2015-04-22
IL235738B (en) 2019-02-28
US10317408B2 (en) 2019-06-11
BR112014031143B1 (pt) 2022-03-03
CA2873278A1 (en) 2013-12-19
DE13731071T1 (de) 2016-08-18
IL235738A0 (en) 2015-01-29
WO2013186374A1 (en) 2013-12-19
KR20150023760A (ko) 2015-03-05
CA2873278C (en) 2021-10-26
AU2013276470B2 (en) 2018-06-07
KR102179848B1 (ko) 2020-11-17
EP2861986B1 (en) 2021-11-10
JP6449765B2 (ja) 2019-01-09
US20150153349A1 (en) 2015-06-04
SG11201408107RA (en) 2015-01-29
JP2015525349A (ja) 2015-09-03
CN104541167B (zh) 2018-05-01

Similar Documents

Publication Publication Date Title
EP2861986B1 (en) Method for quantifying immune cells in tumoral tissues and its applications
US20220051804A1 (en) Image Analysis for Breast Cancer Prognosis
CA2604317C (en) Methods and system for validating sample images for quantitative immunoassays
Braun et al. Quantification of protein expression in cells and cellular subcompartments on immunohistochemical sections using a computer supported image analysis system
ES2542106T3 (es) Método para preparar videomicroscopía cuantitativa y sistema asociado
JP5866362B2 (ja) 画像解析による固形腫瘍進行の予後検査
EP3117259B1 (en) Assessment of staining quality
US20240310379A1 (en) A method for measuring a prognostic marker in prostate cancer or in breast cancer
KR20150023808A (ko) 조직 절편 내 단일 세포에서의 마커 정량
Jing et al. Validity and reliability of Ki-67 assessment in oestrogen receptor positive breast cancer
Jiang et al. Comparative study of different software in Ki67 assessment of breast cancer
Balkenhol et al. Prognostic value of deep learning based mitotic count in hormonal receptor-and HER2-positive breast cancer
Pinder et al. HER2 testing in the UK: further update to
Baban et al. Clinical & Medical